What is Retatrutide?
Summary
Retatrutide (LY3437943) is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes. With an extended half-life of ~6 days, it allows weekly subcutaneous administration.
Substance Properties
What is Retatrutide?
Retatrutide (LY3437943) is a novel triple-agonism peptide simultaneously targeting three receptors: GLP-1, GIP, and glucagon. Developed by Eli Lilly for obesity and type 2 diabetes treatment. The triple-agonism approach is considered the 'next generation' after dual agonists like tirzepatide.
Mechanism of action: Triple agonism
GLP-1 reduces appetite and slows gastric emptying. GIP improves insulin sensitivity and may enhance GLP-1 actions. Glucagon increases thermogenesis and energy expenditure. The combination of all three theoretically leads to greater weight loss than mono- or dual agonists.
Clinical results: Phase 2
In the phase 2 trial (NEJM, 2023), participants receiving the maximum retatrutide dose (12 mg/week) lost an average of ~24% body weight in 48 weeks — one of the highest rates observed in an anti-obesity drug clinical trial. Improvements were also noted in HbA1c, triglycerides, and blood pressure.
Comparison with Semaglutide and Tirzepatide
Semaglutide (GLP-1 mono-agonist) achieves ~15% weight loss. Tirzepatide (dual GLP-1/GIP) ~20-22%. Retatrutide (triple GLP-1/GIP/glucagon) ~24% in phase 2 data. However, head-to-head phase 3 comparisons will be critical.
Safety and side effects
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation — similar to other GLP-1 agonists. Gradual dose escalation significantly reduces severity. No serious safety concerns were reported in phase 2.
Related Guides
Frequently Asked Questions (FAQ)
When will Retatrutide be approved?
Phase 3 results are expected 2025-2026. Potential FDA approval could come 2026-2027, depending on results.
How does it compare to Ozempic/Wegovy?
Retatrutide shows greater weight loss (~24% vs ~15%) but this is based on phase 2 data. Head-to-head phase 3 trials will provide more reliable comparisons.
Does it require dose titration?
Yes. Gradual dose escalation over 12+ weeks (starting from 2 mg/week) is recommended to optimize tolerability and minimize gastrointestinal side effects.
References & Studies
Disclaimer
This article is exclusively educational. It does not constitute medical advice. Retatrutide is not yet an approved drug.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer